RELEVANCE – ‘Regulation of red cell life-span, erythropoiesis, survival, senescence and clearance’ is a 4-year Innovative Training Network project funded by the EC under the Marie Skłodowska-Curie actions. The aim of RELEVANCE is to build a team of 15 early stage researchers (ESRs), educate them, and engage into interactive multidisciplinary work. RELEVANCE consists of an international consortium of thirteen partners from academic research centres, diagnostic labs, blood supply centres, and small industries, combining basic and translational research to improve prognostic, diagnostic and therapeutic approaches on red blood cells production, function, and clearance in healthy humans and patients. Almost half of the 13 consortium partners are also members of the CoMMiTMenT project consortium.
The European Network for Rare and Congenital Anaemias (ENERCA) is funded by the European Commission, with the purpose of offering an improved public health service to professional medical practitioners and patients in every aspect of rare anaemias. The CoMMiTMenT project is closely connected to enerca: the Hospital Clinic Barcelona (IDIBAPS) and the University Medical Center Utrecht are main beneficiary and associated partner of the initiative, respectively.
The European Red Cell Society (ERCS, formerly known as European Association for Red Cell Research EARCR) aims to establish a network of researchers and relevant stakeholders within the red cell research community in order to efficiently address scientific challenges that are common among different areas of RC research. Several institutions participating in CoMMiTMenT are also active members of the ERCS.
The European School of Hematology (ESH) is a non-profit institution for continuing education founded in 1986, to promote and facilitate access to state of the art and cutting-edge knowledge in haematology and related disciplines, at the European level. The director of the school, Prof. Didi Jasmin, is a member of the CoMMiTMenT scientific advisory board.
The International Rare Diseases Research Consortium (IRDiRC) teams up researchers and organizations investing in rare diseases research in order to achieve two main objectives by the year 2020, namely to deliver 200 new therapies for rare diseases and means to diagnose most rare diseases. Through its proposed activities, the CoMMiTMenT project will substantially contribute to the IRDiRC objectives.
Orphanet is the reference portal for information on rare diseases and orphan drugs, for all audiences. Orphanet’s aim is to help improve the diagnosis, care and treatment of patients with rare diseases.
The p-medicine project – 'From data sharing and integration via VPH models to personalized medicine' is a 4-year Integrated Project co-funded under the European Community’s 7th Framework Programme aiming at developing new tools, IT infrastructure and VPH models to accelerate personalized medicine for the benefit of the patient. The coordinator of p-medicine, Prof. Norbert Graf, is a member of the CoMMiTMenT scientific advisory board.
The CordiLux project is aimed at providing a novel in vitro model to analyze human-specific cardiotoxic drug effects as alternative to animal studies. The approach is based on optical methods that monitor isolated cardiomyocytes and measure their reactions to new potential drugs. The German Federal Ministry of Education is providing around 2.5 million € in funding for this initiative. Saarland University and Arivis AG, two members of the CoMMiTMenT consortium are contributing to CordiLux.